Bemarituzumab is a monoclonal antibody (mAb) and from what you posted regarding the instances of grade 3 adverse effects then its behaving just the same as most other mAbs including those others which form the backbone of immunotherapy at present. As they were not produced by the body they tend to be poorly tolerated.
What Imugene is doing with IMU-131 (HER-Vaxx) is a totally different approach (also a different target), the idea is that multiple B-Cell peptide epitopes (structures that the immune system can recognize and bind to) from the HER2/neu receptor (the target receptor on relevant cancer cells, when bound to it halts cell proliferation) can be linked to an adjuvant (thing that angries up the immune system, a molecule from diptheria in this case) as part of a vaccine. The result should be that the immune system starts churning out antibodies that bind to all three epitopes (increases likelihood of success), as these antibodies were made by your own immune system they should be well tolerated.
We know for a fact that IMU-131 results in a robust and specific immune response and hits the right target (Look at Figure 8 in the paper here (https://bmccancer.biomedcentral.com/articles/10.1186/s12885-017-3098-7) It retards a HER2/neu overexpressing cancer cell line just as much as its mAb competition (Trastuzumab - 'Herceptin'), more so in combination.
We also know that it is well tolerated in humans following the Phase 1b trials which found no dose limiting toxicity or any severe adverse event. Of the 11 evaluable patients, one had a complete response (disappearance of all target lesions), five had a partial response (at least a 30% reduction in tumor size), four had stable disease (no significant increase or decrease) and one had progressive disease (at lease 20% increase in tumor size). (https://oncologypro.esmo.org/meeting-resources/esmo-asia-congress-2019/a-phase-ib-study-of-imu-131-her2-neu-peptide-vaccine-plus-chemotherapy-in-patients-with-her2-neu-overexpressing-metastatic-or-advanced-adenocarcino)
"We suggest that the overall response rate (34%) and clinical benefit rate (48%) to first-line trastuzumab monotherapy are significantly higher than those stated by Adams et al. (1)(which was about 15%) and that these are the benchmarks against which the efficacy of newer HER2-targeted agents should be measured in clinical settings." (https://cancerres.aacrjournals.org/content/65/5/2044)
Herceptin is about a $6-7B USD per year drug in sales.
I'll leave it at that.
- Forums
- ASX - By Stock
- The Big Picture - is it visible ?
Bemarituzumab is a monoclonal antibody (mAb) and from what you...
-
- There are more pages in this discussion • 87 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMU (ASX) to my watchlist
|
|||||
Last
5.7¢ |
Change
0.003(5.56%) |
Mkt cap ! $417.2M |
Open | High | Low | Value | Volume |
5.5¢ | 5.8¢ | 5.2¢ | $2.499M | 45.00M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 1921794 | 5.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.7¢ | 1368288 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 286362 | 0.055 |
9 | 2036888 | 0.054 |
16 | 2736044 | 0.053 |
20 | 1943436 | 0.052 |
23 | 3206056 | 0.051 |
Price($) | Vol. | No. |
---|---|---|
0.057 | 378902 | 2 |
0.058 | 1552127 | 7 |
0.059 | 837099 | 8 |
0.060 | 2176188 | 16 |
0.061 | 1163926 | 6 |
Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online